Focused On-demand Library for Glucocorticoid receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Nuclear receptor subfamily 3 group C member 1

Alternative UPACC:

P04150; A0ZXF9; B0LPG8; D3DQF4; F5ATB7; P04151; Q53EP5; Q6N0A4


The Glucocorticoid Receptor, encoded by the gene P04150, is a pivotal protein in mediating the effects of glucocorticoids. It functions as a transcription factor, binding to glucocorticoid response elements in DNA, influencing inflammatory responses, cellular proliferation, and differentiation. Additionally, it plays roles in chromatin remodeling, rapid mRNA degradation, and may act as a tumor suppressor.

Therapeutic significance:

Linked to the disease Glucocorticoid resistance, generalized, the Glucocorticoid Receptor's aberrations result in altered cortisol levels, impacting metabolic processes and stress responses. Understanding its mechanisms opens avenues for targeted therapies in cortisol-related disorders, offering hope for personalized medicine in combating these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.